NBRV stock forecast
Our latest prediction for Nabriva Therapeutics Plc's stock price was made on the Sept. 18, 2017 when the stock price was at 8.87$.
In the short term (2weeks), NBRV's stock price should outperform the market by 4.44%. During that period the price should oscillate between -9.55% and +14.05%.
In the medium term (3months), NBRV's stock price should outperform the market by 3.87%. During that period the price should oscillate between -19.09% and +32.00%.Get email alerts
About Nabriva Therapeutics Plc
Nabriva Therapeutics Plc is a clinical stage biopharmaceutical company, which engages in the research and development of novel antibiotics to treat serious infections. Its product pipeline includes Lefamulin, CONTEPO, and BC-7013. The company was founded in October 2005 and is headquartered in Dublin, Ireland.
At the moment the company generates 1M USD in revenues.
On its last earning announcement, the company reported a loss of -2.04$ per share.
The book value per share is 1.12$
Three months stock forecastSept. 18, 2017
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|